Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Bringing Private Payers To The Regulatory Table: FDA Reaches Out To Insurers

This article was originally published in The Gray Sheet

Executive Summary

The agency's device center put out a request to health insurers to make themselves available to participate in FDA pre-submission meetings so that device firms, particularly start-ups, can better understand data expectations for coverage while companies are still designing studies to support FDA approval.


Related Content

US FDA: Calling All Digital Health Gurus
Payers Want Access To US FDA's Pre-Submission Meetings
FDA Plans For Private-Payer Meetings Ahead, But Roadblocks Remain
FDA MDUFA III Performance, By The Numbers
CDRH Preps New Program To Streamline Approval-To-Reimbursement Path
FDA-CMS Parallel Review Saves Time, Clinical Trial Costs, Participant Says
CDRH Entrepreneurs Take Two: Streamlining Data Collection And The Path To Reimbursement
Device Firms Weigh Pros And Cons Of FDA-CMS Parallel Review





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts